XSNX

NovAccess Global Inc. [XSNX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XSNX Stock Summary

Top 10 Correlated ETFs

XSNX

Top 10 Correlated Stocks

XSNX

In the News

XSNX Financial details

Company Rating
-
Market Cap
283.65K
Income
-789.95K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.4
Forward P/E
-
PEG
0.02
P/S
-
P/B
-0.07
P/C
-
P/FCF
-0.66
Quick Ratio
0.02
Current Ratio
0.03
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-742.46%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-168.63%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-615%
ROE
18%
ROC
0.38%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0081-0.22
52W High
-
52W Low
-
RSI
37.98
Rel Volume
0.03
Avg Volume
355.07K
Volume
10K
Perf Week
33.33%
Perf Month
100%
Perf Quarter
-94.97%
Perf Half Y
-92.45%
-
-
-
-
Beta
1.458
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0004
Change
0%

Something similar

Top by Market Cap
TSLA
ABEA.DE
3V64.DE
BRK-A
META
Top Correlated ETFs
USVL.L
SGWS.L
SUWS.L
FUSD.L
Top Correlated Stocks
AQ.ST
Similar Market Cap
DISL.BR
XSNX
TWER
BDPT
AWYX

Company Profile

Healthcare Biotechnology
  • Volume Average 355.07K
  • Market Capitalization 283.65K
  • Employee 3
  • CEO Dr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D.
  • Headquarters Chesterland,OH,US
  • IPO Date 1998-09-21
  • Website https://novaccessglobal.com

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in Chesterland, Ohio.